Ocular Therapeutix (OCUL) Preferred Dividend Payments (2013 - 2014)
Ocular Therapeutix (OCUL) posted quarterly Preferred Dividend Payments of $5000.0 for Q2 2014, up 155.56% year-over-year from $1956.5 in Q2 2013, and down 16.67% on a QoQ basis from $6000.0 in Q1 2014.
Ocular Therapeutix (OCUL) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Ocular Therapeutix has reported Preferred Dividend Payments for 2 years, with the latest figure at $5000.0 in Q2 2014.
- Preferred Dividend Payments for Q2 2014 came in at $5000.0, up 155.56% year-over-year; the trailing twelve-month figure through Dec 2014 was $11000.0 (changed N/A YoY), and the FY2014 annual result was $11000.0, up 140.74% from the prior year.
- Preferred Dividend Payments retreated to $5000.0 in Q2 2014, from $6000.0 in the prior quarter.
- Over five years, Preferred Dividend Payments peaked at $6000.0 in Q1 2014 and troughed at -$9000.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 5,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Dec 31, 2013 | 49,000.00 |
| Sep 30, 2013 | -5,000.00 |
| Jun 30, 2013 | -9,000.00 |